The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, has announced key trends for the life science industry in 2019 based on The Life Sciences Innovation Report, developed with Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation. According to the report, multi-disciplinary innovation, the implementation of new technologies, new approaches to research, the digitisation of R&D and healthcare, and academic contributions to biologics drug R&D are all key trends in the life sciences industry.
Members of The Pistoia Alliance helped to create the report, which includes analysis driven by Cortellis, a suite of intelligence solutions for drug development and commercialisation provided by Clarivate Analytics. Key contributors include executives from leading life science organisations such as Cancer Research UK, GlaxoSmithKline, AbbVie, and Diavics. The overarching theme of all emerging trends for 2019 is the continuing need for greater cross-industry collaboration to realise the potential in these areas.
According to the findings of the report, innovation is being driven via collaboration from multiple industry stakeholders. The emergence and development of new tools like nanosensors, bi-specific antibodies and computational biology have highlighted the success that can be achieved from collaboration between researchers and organisations across a range of disciplines. This trend will continue in 2019.
Technologies are being adopted to advance drug research. The report findings show budgets will continue to increase to allow for new technological advances, including the use of artificial intelligence in R&D decision making. Research from The Pistoia Alliance has already shown growth in the implementation of AI and blockchain.
Further, the report notes that new types of research are coming to the forefront. Research in precision medicine, immunotherapy and the microbiome are opening up new discovery pathways. Alongside genomic research, these new approaches will provide a more refined understanding of diseases, better diagnoses and improvements to treatment.
Digitisation of R&D and healthcare will increase, says the report. R&D functions are already beginning to adopt large-scale use of cloud-based platforms, but this will accelerate this year. Mobile computing is poised to support the digitisation of health in combination with drug therapy, as well as through stand-alone therapies.
Additionally, the report notes that academia is increasingly contributing to biologics R&D. Academia has already made significant contributions to scientific innovation across genetic and cellular therapies, with antibodies, CAR-T and CRISPR-Cas9 all leading to new approaches to potential novel biological therapies. The role of academia will become more vital as researchers look to expand on existing research.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
